Verispan Reports: Over 34,000 Prescribers Switch Patients From Vioxx To Other COX-2 Inhibitors In First Days After Recall

Verispan's Vector One(TM) reports that in the first few days following the Sept. 30 recall of Merck's COX-2 inhibitor Vioxx, over 34,100 distinct prescribers switched a projected 110,000 patients to other COX-2 inhibitors.